Skip to main content
Fig. 5 | Respiratory Research

Fig. 5

From: Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial

Fig. 5

ACQ-5 Least squares mean change from baseline versus placebo on Day 15 (full analysis set). Baseline was defined separately for each treatment period as the pre-dose score on day 1 of each treatment period. Error bars represent 95% confidence intervals. * p < 0.05, ** p < 0.001, NS not significant, QD once daily, ACQ-5 Asthma Control Questionnaire-5

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us